TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Completed
The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2011
Locations: The Sarah Cannon Cancer Center, Nashville, Tennessee
Conditions: Non-small Cell Lung Cancer
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Lung Cancer
Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
Completed
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2009
Locations: Vanderbilt Universtiy Medical Center, Nashville, Tennessee
Conditions: Advanced Solid Tumors